Prevention of Recurrent Stroke

  • N. M. Bornstein
  • A. D. Korczyn

Abstract

Cerebrovascular disease (CVD) is the third leading cause of death in the developed world and represents a major cause of disability in the aged. In the United States, CVD ranks as the eighth cause of years of potential life lost before age 65.1 The 1989 edition of a popular brochure “Stroke Facts” states: “In America someone dies of cardiovascular disease every 32 seconds. In 1986 nearly one out of two Americans died of heart and vascular disease; stroke claimed 147,000 lives in 1986. Stroke accounts for half of all patients hospitalized for acute neurological disease. Stroke related health care in 1989 is estimated by the American Heart Association at 13.5 billion dollars.” Detailed, accurate knowledge of the natural history of stroke, its incidence, and management is required to predict outcome and evaluate treatment.

Keywords

Atrial Fibrillation Ischemic Stroke Carotid Endarterectomy Recurrent Stroke European Stroke Prevention Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Center of Disease Control. Premature mortality due to cerebrovascular disease — United States, 1983. JAMA. 1987;258:182.CrossRefGoogle Scholar
  2. 2.
    Dyken ML, Wolf PA, Barnett HJM, et al. Risk factors in stroke, a statement for physicians by the subcommittee on risk factors and stroke of the stroke council. Stroke. 1984;15:1105–1111.CrossRefGoogle Scholar
  3. 3.
    Whisnant JP. The role of the neurologist in the decline of stroke. Ann Neurol. 1983;14:1–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Whisnant JP. The decline of stroke. Stroke. 1984; 15:160–168.PubMedCrossRefGoogle Scholar
  5. 5.
    Garraway WM, Whisnant JP. The changing pattern of hypertension and the declining incidence of stroke. JAMA. 1987;258:214–217.PubMedCrossRefGoogle Scholar
  6. 6.
    Hachinski V. Decreased incidence and mortality of stroke. Stroke. 1984;15:376–378.PubMedCrossRefGoogle Scholar
  7. 7.
    Howard G, Toole JF, Becker C, et al. Changes in survival following stroke in five North Carolina counties observed during different periods. Stroke. 1989;20:345–350.PubMedCrossRefGoogle Scholar
  8. 8.
    Ahmed OI, Orchard TJ, Sharma R, et al. Declining mortality from stroke in Allegheny County, Pennsylvania. Trends in case fatality and severity of disease, 1971–1980. Stroke. 1988;19:181–184.PubMedCrossRefGoogle Scholar
  9. 9.
    Baum HM, Robins M. National Survey of Stroke. Survival and prevalence. Stroke. 1981;12(suppl 1):59–68.Google Scholar
  10. 10.
    Cooper SE. Stroke mortality declines; still major health problem. JAMA. 1984;252:594.CrossRefGoogle Scholar
  11. 11.
    Bonita R, Stewart A, Beaglehole R. International trends in stroke mortality: 1970–1985. Stroke. 1990; 21:989–992.PubMedCrossRefGoogle Scholar
  12. 12.
    Epstein L, Zaaroor M. Mortality from ischemic heart disease and cerebrovascular disease in Israel 1969 – 1978. Stroke. 1982;13:570–573.PubMedCrossRefGoogle Scholar
  13. 13.
    Pisa Z, Uemurat K. Trends in mortality from ischemic heart disease and other cardiovascular disease in 27 countries. World Health State Q. 1982;35:11–49.Google Scholar
  14. 14.
    Dyken ML. ‘Natural’ history of ischemic stroke. In: Cerebral Vascular Disease, eds MJG Harrison and ML Dyken, Butterworths, London, 1983, pp 139–170.Google Scholar
  15. 15.
    Chambers BR, Norris JW, Shurvell BL, et al. Prognosis of acute stroke. Neurology. 1987;37:221–225.PubMedCrossRefGoogle Scholar
  16. 16.
    Sacco RL, Wolf PA, Kannel WB, et al. Survival and recurrence following stroke, the Framingham study. Stroke. 1982;13:290–295.PubMedCrossRefGoogle Scholar
  17. 17.
    Terent A. Increasing incidence of stroke among Swedish women. Stroke. 1988;19:598–603.PubMedCrossRefGoogle Scholar
  18. 18.
    Leonberg SC, Elliott FA. Prevention of recurrent stroke. Stroke. 1981;12:731–735.PubMedCrossRefGoogle Scholar
  19. 19.
    Meissner I, Whisnant JP, Garraway WM. Hypertension management and stroke recurrence in community (Rochester, Minnesota, 1950–1979). Stroke. 1988;19:459–463.PubMedCrossRefGoogle Scholar
  20. 20.
    Schmidt EV, Smirnov VE, Ryabova VS. Results of the seven-years prospective study of stroke patients. Stroke. 1988;19:942–949.CrossRefGoogle Scholar
  21. 21.
    Matsumoto N, Whisnant JP, Kurland LT, et al. Natural history of stroke in Rochester, Minnesota, 1955 through 1969: an extension of a previous study, 1945 through 1954. Stroke. 1973;4:20–29.PubMedCrossRefGoogle Scholar
  22. 22.
    Baker RN, Schwartz WS, Ramseyer JC. Prognosis among survivors of ischemic stroke. Neurology. 1968;18:933–941.PubMedCrossRefGoogle Scholar
  23. 23.
    Viitanen M, Eriksson S, Asplund K. Risk of recurrent stroke, myocardial infarction and epilepsy during long-term follow-up after stroke. Eur Neurol. 1988;28:227–731.PubMedCrossRefGoogle Scholar
  24. 24.
    Homer D, Whisnant JP, Schoenberg BS. Trends in the incidence rates of stroke in Rochester, Minnesota, since 1935. Ann Neurol. 1987;22:245–251.Google Scholar
  25. 25.
    Sobel E, Alter M, Davanipour Z, et al. Stroke in the Lehigh valley: combined risk factors for recurrent ischemic stroke. Neurology. 1989;39:669–672.PubMedCrossRefGoogle Scholar
  26. 26.
    Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA. 1974;229:409–418.CrossRefGoogle Scholar
  27. 27.
    Beevers DG, Hamilton M, Fairmant MJ, et al. Antihypertensive treatment and the course of established cerebral vascular disease. Lancet. 1973;1:1407–1409.PubMedCrossRefGoogle Scholar
  28. 28.
    Davis PH, Dambtosia JM, Schoenberg BS, et al. Risk factors for ischemic stroke: A prospective study in Rochester, Minnesota. Ann Neurol. 1987;22:319–327.PubMedCrossRefGoogle Scholar
  29. 29.
    Alter M, Sobel E, McCoy RL, et al. Stroke in the Lehigh valley: Risk factors for recurrent stroke. Neurology. 1987;37:503–507.PubMedCrossRefGoogle Scholar
  30. 30.
    Solzi P, Ring H, Najenson T, Luz Y. Hemiplegic after a first stroke: Late survival and risk factors. Stroke. 1983;14:703–709.PubMedCrossRefGoogle Scholar
  31. 31.
    Landi G, Barbarotto R, Morabito A, et al. Prognostic significance of fibrinopeptide A in survivors of cerebral infarction. Stroke. 1990;21:424–427.PubMedCrossRefGoogle Scholar
  32. 32.
    Sacco RL, Foulkes MA, Mohr JP, et al. Determinants of early recurrence of cerebral infarction, the Stroke Data Bank. Stroke. 1989;20:983–989.PubMedCrossRefGoogle Scholar
  33. 33.
    The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:53–59.CrossRefGoogle Scholar
  34. 34.
    Bousser MG, Eschwege E, Hagenau M, et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischaemia. Stroke. 1983;14:5–14.PubMedCrossRefGoogle Scholar
  35. 35.
    UKTIA Study Group. United Kingdom transient ischaemic attack (UKTIA) aspirin trial: interim results. Br Med J. 1988;296:316–320.CrossRefGoogle Scholar
  36. 36.
    Sze PC, Reitman D, Pincus MM, et al. Antiplatelet agents in the secondary prevention of stroke: metaanalysis of randomized controlled trials. Stroke. 1988;19:436–442.PubMedCrossRefGoogle Scholar
  37. 37.
    Antiplatelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J. 1988;296:320–331.CrossRefGoogle Scholar
  38. 38.
    The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke. 1988;19:512–517.CrossRefGoogle Scholar
  39. 39.
    ESPS Group. European Stroke Prevention Study. Stroke. 1990;21:1122–1130.CrossRefGoogle Scholar
  40. 40.
    Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215–1220.PubMedCrossRefGoogle Scholar
  41. 41.
    Ostrander LD, Jr., Brandt RL, Kjelsberg MO, et al. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation. 1965; 31:888–898.PubMedCrossRefGoogle Scholar
  42. 42.
    Cardiogenic Brain Embolism. The second report of the cerebral embolism task force. Arch Neurol. 1989;46:727–743.CrossRefGoogle Scholar
  43. 43.
    Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke. 1988;19: 937–941.PubMedCrossRefGoogle Scholar
  44. 44.
    Wolf PA, Kannel WB, McGee DL, et al. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke. 1983;14:664–667.PubMedCrossRefGoogle Scholar
  45. 45.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contribution to stroke in the elderly. Arch Intern Med. 1987;147:1561–1564.PubMedCrossRefGoogle Scholar
  46. 46.
    Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol. 1986;43:71–84.CrossRefGoogle Scholar
  47. 47.
    Kelley RE, Berger JR, Alter M, et al. Cerebral ischemia and atrial fibrillation: prospective study. Neurology. 1984;34:1285–1291.PubMedCrossRefGoogle Scholar
  48. 48.
    Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation, the Framingham study. N Engl J Med. 1982;306:1018–1022.PubMedCrossRefGoogle Scholar
  49. 49.
    Lodder J, Dennis MS, Van Raak L, et al. Cooperative study on the value of long term anticoagulation in patients with stroke and non-rheumatic atrial fibrillation. Br Med J. 1988;296:1435–1438.CrossRefGoogle Scholar
  50. 50.
    Petersen P, Boysen G, Godtfredsen J, et al. Placebocontrolled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet. 1989;175–179.Google Scholar
  51. 51.
    Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the stroke prevention in atrial fibrillation study. N Engl J Med. 1990;322:863–868.Google Scholar
  52. 52.
    The Boston Area Anticoagulation Trial for Atrial Fibrillation. The effects of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–1511.CrossRefGoogle Scholar
  53. 53.
    The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: Results of an international randomized trial. N Engl J Med. 1985;313:1191–1200.CrossRefGoogle Scholar
  54. 54.
    Eastcott HHG, Pickering GW, Rob CG. Reconstruction of internal carotid artery in a patient with intermittent attacks of hemiplegia. Lancet. 1954;2:994–996.CrossRefGoogle Scholar
  55. 55.
    Pokras R, Dyken ML. Dramatic changes in the performance of endarterectomy for diseases of the extracranial arteries of the head. Stroke. 1988;19: 1289–1290.PubMedCrossRefGoogle Scholar
  56. 56.
    Fields WS, Maslenikov V, Meyer JS, et al. Joint study of extracranial arterial occlusion. JAMA. 1970;211:1993–2003.PubMedCrossRefGoogle Scholar
  57. 57.
    Shaw DA, Venables GS, Cartlidge NEF, et al. Carotid endarterectomy in patients with transient cerebral ischemia. J Neurol Sci. 1984;64:45–53.PubMedCrossRefGoogle Scholar
  58. 58.
    Winslow CM, Solomon DH, Chassin MR, et al. The appropriateness of carotid endarterectomy. N Engl J Med. 1988;318:721–727.PubMedCrossRefGoogle Scholar
  59. 59.
    Beebe HG, Clagett GP, DeWeese JA, et al. Assessing risk associated with carotid endarterectomy. A statement for health professionals by an Ad Hoc Committee on Carotid Surgery Standards of the Stroke Council, American Heart Association. Stroke. 1989;20:314–315.Google Scholar
  60. 60.
    American Academy of Neurology, Therapeutics and Technology Assessment Subcommittee. Interim assessment: carotid endarterectomy. Neurology. 1990;40:682–683.CrossRefGoogle Scholar
  61. 61.
    Committee on Health Care Issues, American Neurological Association. Does carotid endarterectomy decrease stroke and death in patients with transient ischemic attacks? Ann Neurol. 1987; 22:72–76.CrossRefGoogle Scholar
  62. 62.
    Caplan LR. Carotid-artery disease. N Engl J Med. 1986;315:886–887.PubMedCrossRefGoogle Scholar
  63. 63.
    Callow AD, Caplan LR, Correll JW, et al. Carotid endarterectomy: what is its current status? Am J Med. 1988;85:835–838.PubMedCrossRefGoogle Scholar
  64. 64.
    Barnett HJM, Plum F, Walton JN. Carotid endarterectomy-an expression of concern. Stroke. 1984;15: 941–943.PubMedCrossRefGoogle Scholar
  65. 65.
    Califano JA Jr. Billions blown on health. New York Times; 12 April 1989.Google Scholar
  66. 66.
    Lundtyke MA. Physician-inform thyself. New York Times; 16 April 1989.Google Scholar
  67. 67.
    Thompson JE. Don’t throw out the baby with the bath water. A perspective on carotid endarterectomy. J Vasc Surg. 1986;4:543–545.PubMedGoogle Scholar
  68. 68.
    Robins M, Baum HM. Incidence. National Survey of Stroke. Stroke. 1981;12 (suppl 1):1–45–55.CrossRefGoogle Scholar
  69. 69.
    Cooper R, Hsieh SC. Slowdown in the decline of stroke mortality in the United States, 1978–1986. Stroke 1990;21:1274–1279.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • N. M. Bornstein
  • A. D. Korczyn

There are no affiliations available

Personalised recommendations